Protagonist TherapeuticsPTGX
About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Employees: 126
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
225% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 24
35% more capital invested
Capital invested by funds: $2.07B [Q2] → $2.8B (+$728M) [Q3]
27% more funds holding
Funds holding: 187 [Q2] → 238 (+51) [Q3]
19% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 64
3.69% more ownership
Funds ownership: 101.94% [Q2] → 105.64% (+3.69%) [Q3]
45% less call options, than puts
Call options by funds: $2.83M | Put options by funds: $5.18M
50% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 4 (-4) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
JMP Securities Jonathan Wolleben 43% 1-year accuracy 32 / 75 met price target | 49%upside $58 | Market Outperform Reiterated | 7 Feb 2025 |
HC Wainwright & Co. Douglas Tsao 34% 1-year accuracy 61 / 178 met price target | 29%upside $50 | Buy Reiterated | 7 Feb 2025 |
JP Morgan Brian Cheng 29% 1-year accuracy 6 / 21 met price target | 36%upside $53 | Overweight Maintained | 4 Feb 2025 |
BMO Capital Etzer Darout 22% 1-year accuracy 9 / 41 met price target | 59%upside $62 | Outperform Initiated | 6 Dec 2024 |
Financial journalist opinion









